Anthony Coia
Anthony holds an MD from the Johns Hopkins School of Medicine where he focused on internal medicine and regenerative research, an MBA from the Kellogg School of Management where he focused on strategy, finance and decision analysis, and a BS in Mechanical and Aerospace Engineering from Syracuse University (Tau Beta Pi, magna cum laude).
Prior to medical school, Anthony was an officer in the United States Air Force, where he served as an aviator in the F-111 airframe. He was discharged from the USAF having received the Air Force Achievement Medal for Leadership.
He was also an active volunteer for the Southwest Corridor Park Conservancy, part of Frederick Law Olmsted's Emerald Necklace, a series of parks, in Boston.
As Global Senior Director with Novartis in in Basel, Switzerland, Tony evaluates innovative external assets to build the firm's internal portfolio within inflammation/autoimmunity, dermatology, and cell-therapy areas. He also leads evaluations for senior management on possible acquisitions. Earlier, Tony was Senior Global Director of Marketing and New Products where he led commercialization and marketing efforts for multiple therapeutic assets focused on chronic conditions, and set strategy and performed tactical planning for new product development.
Previously, Tony was a Principal with BioVentures Investors in Boston where he led due diligence efforts and held Board seats with companies in the BVI2 and BVI3 Funds. He led a number of investments and participated actively in efforts with CardioSolutions, Claros Diagnostics, Cylene Pharmaceuticals, Enanta Pharmaceuticals, Spirus Medical, Hydra Biosciences, Rcadia Medical Imaging, Hydrocision, Verax Biomedical, Vital Sensors, and Momelan Technologies.
Before venture, Tony was with L.E.K. Consulting, working with pharmaceutical, biotech, and private equity clients on projects that addressed asset valuation, strategic planning, and investment due diligence. He was also the Director of Technology Development for Partners Healthcare, where he helped to commercialize technology from the Massachusetts General Hospital (MGH) and the Brigham and Women's Hospital (BWH).
Tony has conducted research in the areas of neurodegenerative disease with the University of Pennsylvania and in regenerative medicine with the Johns Hopkins Hospital. During business school, he also co-authored work published in the journal Nature Biotech on the subject of 'Value Drivers in Licensing Deals' (Nov. 2002).
A member of Class 14, Anthony served his fellowship under mentor Marc Goldberg at BioVentures Investors.